Cargando…

A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer

PURPOSE: This study aimed to assess the diagnostic performance and the added value to radiologists of different levels of a computer-aided diagnosis (CAD) system for the detection of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with breast cancer. Besides, to...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Haiyong, Yan, Shaolei, Chen, Xiaodan, Hu, Jiahang, Chen, Kaige, Wang, Ping, Zhang, Hongxia, Zhang, Xiushi, Meng, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928462/
https://www.ncbi.nlm.nih.gov/pubmed/35311124
http://dx.doi.org/10.3389/fonc.2022.784839
_version_ 1784670646221930496
author Peng, Haiyong
Yan, Shaolei
Chen, Xiaodan
Hu, Jiahang
Chen, Kaige
Wang, Ping
Zhang, Hongxia
Zhang, Xiushi
Meng, Wei
author_facet Peng, Haiyong
Yan, Shaolei
Chen, Xiaodan
Hu, Jiahang
Chen, Kaige
Wang, Ping
Zhang, Hongxia
Zhang, Xiushi
Meng, Wei
author_sort Peng, Haiyong
collection PubMed
description PURPOSE: This study aimed to assess the diagnostic performance and the added value to radiologists of different levels of a computer-aided diagnosis (CAD) system for the detection of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with breast cancer. Besides, to investigate whether tumor molecular typing is associated with the efficiency of diagnosis of the CAD systems. METHODS: 470 patients were identified with breast cancers who underwent NAC and post MR imaging between January 2016 and March 2019. The diagnostic performance of radiologists of different levels and the CAD system were compared. The added value of the CAD system was assessed and subgroup analyses were performed according to the tumor molecular typing. RESULTS: Among 470 patients, 123 (26%) underwent pCR. The CAD system showed a comparable specificity as the senior radiologist (83.29% vs. 84.15%, p=0.488) and comparable area under the curve (AUC) (0.839 vs. 0.835, p =0.452). The performance of all radiologists significantly improved when aided by the CAD system (P<0.05), And there were no statistical differences in terms of sensitivity, specificity and accuracy between the two groups with CAD assistance(p>0.05).The AUC values for identifying pCR in TN patients were significant (0.883, 95%CI: 0.801-0.964, p < 0.001). CONCLUSION: The CAD system assessed in this study improves the performance of all radiologists, regardless of experience. The molecular typing of breast cancer is potential influencer of CAD diagnostic performance.
format Online
Article
Text
id pubmed-8928462
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89284622022-03-18 A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Peng, Haiyong Yan, Shaolei Chen, Xiaodan Hu, Jiahang Chen, Kaige Wang, Ping Zhang, Hongxia Zhang, Xiushi Meng, Wei Front Oncol Oncology PURPOSE: This study aimed to assess the diagnostic performance and the added value to radiologists of different levels of a computer-aided diagnosis (CAD) system for the detection of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with breast cancer. Besides, to investigate whether tumor molecular typing is associated with the efficiency of diagnosis of the CAD systems. METHODS: 470 patients were identified with breast cancers who underwent NAC and post MR imaging between January 2016 and March 2019. The diagnostic performance of radiologists of different levels and the CAD system were compared. The added value of the CAD system was assessed and subgroup analyses were performed according to the tumor molecular typing. RESULTS: Among 470 patients, 123 (26%) underwent pCR. The CAD system showed a comparable specificity as the senior radiologist (83.29% vs. 84.15%, p=0.488) and comparable area under the curve (AUC) (0.839 vs. 0.835, p =0.452). The performance of all radiologists significantly improved when aided by the CAD system (P<0.05), And there were no statistical differences in terms of sensitivity, specificity and accuracy between the two groups with CAD assistance(p>0.05).The AUC values for identifying pCR in TN patients were significant (0.883, 95%CI: 0.801-0.964, p < 0.001). CONCLUSION: The CAD system assessed in this study improves the performance of all radiologists, regardless of experience. The molecular typing of breast cancer is potential influencer of CAD diagnostic performance. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8928462/ /pubmed/35311124 http://dx.doi.org/10.3389/fonc.2022.784839 Text en Copyright © 2022 Peng, Yan, Chen, Hu, Chen, Wang, Zhang, Zhang and Meng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Peng, Haiyong
Yan, Shaolei
Chen, Xiaodan
Hu, Jiahang
Chen, Kaige
Wang, Ping
Zhang, Hongxia
Zhang, Xiushi
Meng, Wei
A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
title A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
title_full A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
title_fullStr A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
title_full_unstemmed A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
title_short A Clinical Assessment of a Magnetic Resonance Computer-Aided Diagnosis System in the Detection of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer
title_sort clinical assessment of a magnetic resonance computer-aided diagnosis system in the detection of pathological complete response after neoadjuvant chemotherapy in breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928462/
https://www.ncbi.nlm.nih.gov/pubmed/35311124
http://dx.doi.org/10.3389/fonc.2022.784839
work_keys_str_mv AT penghaiyong aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT yanshaolei aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT chenxiaodan aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT hujiahang aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT chenkaige aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT wangping aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT zhanghongxia aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT zhangxiushi aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT mengwei aclinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT penghaiyong clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT yanshaolei clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT chenxiaodan clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT hujiahang clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT chenkaige clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT wangping clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT zhanghongxia clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT zhangxiushi clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer
AT mengwei clinicalassessmentofamagneticresonancecomputeraideddiagnosissysteminthedetectionofpathologicalcompleteresponseafterneoadjuvantchemotherapyinbreastcancer